Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Leukoencephalopathy and Disseminated Necrotizing Leukoencephalopathy Following Intrathecal Methotrexate Chemotherapy and Radiation Therapy for Central Nerve System Lymphoma or Leukemia

  • Kim, Ji-Yeon (Department of Neurosurgery, Center for Imaging Science, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Kim, Sung-Tae (Department of Radiology, Center for Imaging Science, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Nam, Do-Hyun (Department of Neurosurgery, Center for Imaging Science, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Lee, Jung-Il (Department of Neurosurgery, Center for Imaging Science, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Park, Kwan (Department of Neurosurgery, Center for Imaging Science, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine) ;
  • Kong, Doo-Sik (Department of Neurosurgery, Center for Imaging Science, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine)
  • Received : 2010.10.28
  • Accepted : 2011.03.21
  • Published : 2011.10.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : Intrathecal methotrexate (MTX) therapy combined with whole brain radiotherapy (WBRT) is one of the major treatment modalities for leukemia and lymphoma involving the central nervous system (CNS). The purpose of this study was to retrospectively determine the incidences of leukoencephalopathy and disseminated necrotizing leukoencephalopathy (DNL) following intrathecal MTX therapy for CNS lymphoma or leukemia and to assess the potential risk factors. Methods : Between January 2000 and August 2009, 143 patients with CNS lymphoma or leukemia received intrathecal MTX therapy alone or in combination with WBRT at a single institution. Patients were followed up clinically and radiologically at regular two- or three-month intervals. Medical records were reviewed to obtain information regarding the patients' demographics, medical histories, radiologic characteristics, treatments, and clinical courses. Results : On follow-up MR images, leukoencephalopathy was found in 95 of 143 patients (66.4%). The median time to develop leukoencephalopathy was 6.6 months. Among those with leukoencephalopathy, four patients showed seven extensive white-matter changes with strongly enhancing lesions demonstrating DNL. Histological confirmation was done in six lesions of three patients and radiological diagnosis alone in one patient. Four lesions spontaneously disappeared on MR images without any treatment, with a mean duration of 14 months before disappearance of DNL. Conclusion : Leukoencephalopathy is a common phenomenon that occurs following intrathecal MTX therapy; however, DNL occurs at a very low incidence. For newly developed enhancing lesions, consideration for the occurrence of DNL should be taken to avoid unnecessary invasive procedures or therapies.

Keywords

References

  1. Antunes NL, Souweidane MM, Lis E, Rosenblum MK, Steinherz PG : Methotrexate leukoencephalopathy presenting as Kluver-Bucy syndrome and uncinate seizures. Pediatr Neurol 26 : 305-308, 2002 https://doi.org/10.1016/S0887-8994(01)00376-9
  2. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al. : Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21 : 1044-1049, 2003 https://doi.org/10.1200/JCO.2003.03.036
  3. Belka C, Budach W, Kortmann RD, Bamberg M : Radiation induced CNS toxicity--molecular and cellular mechanisms. Br J Cancer 85 : 1233-1239, 2001 https://doi.org/10.1054/bjoc.2001.2100
  4. Chen CY, Zimmerman RA, Faro S, Bilaniuk LT, Chou TY, Molloy PT : Childhood leukemia : central nervous system abnormalities during and after treatment. AJNR Am J Neuroradiol 17 : 295-310, 1996
  5. Cossaart N, SantaCruz KS, Preston D, Johnson P, Skikne BS : Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer : a case report and review of the literature. Bone Marrow Transplant 31 : 57-60, 2003 https://doi.org/10.1038/sj.bmt.1703768
  6. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ : Combination chemotherapy and radiotherapy for primary central nervous system lymphoma : Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20 : 4643-4648, 2002 https://doi.org/10.1200/JCO.2002.11.013
  7. Dirks PB, Jay V, Becker LE, Drake JM, Humphreys RP, Hoffman HJ, et al. : Development of anaplastic changes in low-grade astrocytomas of childhood. Neurosurgery 34 : 68-78, 1994 https://doi.org/10.1227/00006123-199401000-00010
  8. Ekenel M, Iwamoto FM, Ben-Porat LS, Panageas KS, Yahalom J, DeAngelis LM, et al. : Primary central nervous system lymphoma : the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 113 : 1025-1031, 2008 https://doi.org/10.1002/cncr.23670
  9. Fassas AB, Gattani AM, Morgello S : Cerebral demyelination with 5-fluorouracil and levamisole. Cancer Invest 12 : 379-383, 1994 https://doi.org/10.3109/07357909409038226
  10. Giglio P, Gilbert MR : Cerebral radiation necrosis. Neurologist 9 : 180-188, 2003 https://doi.org/10.1097/01.nrl.0000080951.78533.c4
  11. Kamiryo T, Lopes MB, Kassell NF, Steiner L, Lee KS : Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 49 : 409-414; discussion 414-415, 2001
  12. Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plasswilm L, Paulsen F, et al. : Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: treatment-related late toxicity. Strahlenther Onkol 179 : 585-597, 2003 https://doi.org/10.1007/s00066-003-8104-0
  13. Kuker W, Bader P, Herrlinger U, Heckl S, Nagele T : Transient encephalopathy after intrathekal methotrexate chemotherapy : diffusion-weighted MRI. J Neurooncol 73 : 47-49, 2005 https://doi.org/10.1007/s11060-004-2929-y
  14. Lai R, Abrey LE, Rosenblum MK, DeAngelis LM : Treatment-induced leukoencephalopathy in primary CNS lymphoma : a clinical and autopsy study. Neurology 62 : 451-456, 2004 https://doi.org/10.1212/01.WNL.0000106941.51340.A2
  15. Laxmi SN, Takahashi S, Matsumoto K, Higano S, Kurihara N, Imaizumi M, et al. : Treatment-related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter. Radiat Med 14 : 303-307, 1996
  16. Matsubayashi J, Tsuchiya K, Matsunaga T, Mukai K : Methotrexate-related leukoencephalopathy without radiation therapy : distribution of brain lesions and pathological heterogeneity on two autopsy cases. Neuropathology 29 : 105-115, 2009 https://doi.org/10.1111/j.1440-1789.2008.00945.x
  17. Moore-Maxwell CA, Datto MB, Hulette CM : Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies. Mod Pathol 17 : 241-247, 2004 https://doi.org/10.1038/modpathol.3800049
  18. Ohmoto Y, Kajiwara K, Kato S, Nisizaki T, Ito H, Tamura S : Atypical MRI findings in treatment-related leukoencephalopathy : case report. Neuroradiology 38 : 128-133, 1996 https://doi.org/10.1007/BF00604796
  19. Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, et al. : MRI in methotrexate-related leukoencephalopathy : Disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45 : 493-497, 2003 https://doi.org/10.1007/s00234-003-0983-3
  20. Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, et al. : Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62 : 1595-1600, 2005 https://doi.org/10.1001/archneur.62.10.1595
  21. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. : Primary central nervous system lymphoma : results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21 : 4489-4495, 2003 https://doi.org/10.1200/JCO.2003.04.056
  22. Perry A, Schmidt RE : Cancer therapy-associated CNS neuropathology : an update and review of the literature. Acta Neuropathol 111 : 197-212, 2006 https://doi.org/10.1007/s00401-005-0023-y
  23. Pimperl LC : Radiation as a nervous system toxin. Neurol Clin 23 : 571-597, 2005 https://doi.org/10.1016/j.ncl.2004.12.006
  24. Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, et al. : Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol 26 : 1263-1269, 2005
  25. Rubinstein JL, Herman MM, Long TF, Wilbur JR : Leukoencephalopathy following combined therapy of central nervous system leukemia and lymphoma. Acta Neuropathol Suppl Suppl 6 : 251-255, 1975
  26. Saykin AJ, Ahles TA, McDonald BC : Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8 : 201-216, 2003
  27. Scheike TH, Zhang MJ : Flexible competing risks regression modeling and goodness-of-fit. Lifetime Data Anal 14 : 464-483, 2008 https://doi.org/10.1007/s10985-008-9094-0
  28. Shuper A, Stark B, Kornreich L, Cohen IJ, Avrahami G, Yaniv I : Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J 4 : 1050-1053, 2002
  29. Tofilon PJ, Fike JR : The radioresponse of the central nervous system: a dynamic process. Radiat Res 153 : 357-370, 2000 https://doi.org/10.1667/0033-7587(2000)153[0357:TROTCN]2.0.CO;2
  30. Wassenberg MW, Bromberg JE, Witkamp TD, Terhaard CH, Taphoorn MJ : White matter lesions and encephalopathy in patients treated for primary central nervous system lymphoma. J Neurooncol 52 : 73-80, 2001 https://doi.org/10.1023/A:1010676807228

Cited by

  1. Methotrexate : Disseminated necrotising leukoencephalopathy following intrathecal administration: 4 case reports vol.1387, pp.1, 2012, https://doi.org/10.1007/bf03294053
  2. Toxic Leukoencephalopathies, Including Drug, Medication, Environmental, and Radiation-Induced Encephalopathic Syndromes vol.35, pp.2, 2011, https://doi.org/10.1053/j.sult.2013.09.005
  3. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study vol.119, pp.2, 2011, https://doi.org/10.1007/s11060-014-1486-2
  4. Cerebrospinal Fluid (CSF) Directed Antineoplastic Agents: A Review of Current Knowledge vol.2, pp.1, 2011, https://doi.org/10.15406/jcpcr.2015.02.00026
  5. Imaging of Nervous System Involvement in Hematologic Malignancies: What Radiologists Need to Know vol.205, pp.3, 2011, https://doi.org/10.2214/ajr.14.14092
  6. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single‐arm study vol.139, pp.8, 2011, https://doi.org/10.1002/ijc.30214
  7. Disseminated Necrotizing Leukoencephalopathy Complicating Septic Shock in an Immunocompetent Patient vol.2017, pp.None, 2011, https://doi.org/10.1155/2017/1092537
  8. S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells vol.52, pp.6, 2011, https://doi.org/10.3892/ijo.2018.4345
  9. Methotrexate-induced Leukoencephalopathy without Typical Restricted Diffusion on Diffusion-weighted Imaging and the Utility of Magnetic Resonance Spectroscopy to Support the Diagnosis vol.13, pp.3, 2011, https://doi.org/10.4103/ajns.ajns_324_16
  10. Imaging Patterns of Toxic and Metabolic Brain Disorders vol.39, pp.6, 2011, https://doi.org/10.1148/rg.2019190016
  11. Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature vol.79, pp.10, 2020, https://doi.org/10.1093/jnen/nlaa099
  12. Recognizing Radiation-induced Changes in the Central Nervous System: Where to Look and What to Look For vol.41, pp.1, 2011, https://doi.org/10.1148/rg.2021200064
  13. Uncertainty of leukoencephalopathies: a case report vol.15, pp.1, 2011, https://doi.org/10.1186/s13256-021-03089-6